406 related articles for article (PubMed ID: 29931409)
1. Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study.
El-Fatatry BM; Ibrahim OM; Hussien FZ; Mostafa TM
Int J Colorectal Dis; 2018 Dec; 33(12):1675-1683. PubMed ID: 29931409
[TBL] [Abstract][Full Text] [Related]
2. L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf-2 and NF-κB pathways.
Yehia R; Saleh S; El Abhar H; Saad AS; Schaalan M
Toxicol Appl Pharmacol; 2019 Feb; 365():41-50. PubMed ID: 30592963
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
[TBL] [Abstract][Full Text] [Related]
4. Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer.
Wang DS; Wang ZQ; Chen G; Peng JW; Wang W; Deng YH; Wang FH; Zhang JW; Liang HL; Feng F; Xie CB; Ren C; Jin Y; Shi SM; Fan WH; Lu ZH; Ding PR; Wang F; Xu RH; Li YH
Cancer Med; 2020 Jan; 9(1):151-159. PubMed ID: 31724334
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients.
Nagashima M; Ooshiro M; Moriyama A; Sugishita Y; Kadoya K; Sato A; Kitahara T; Takagi R; Urita T; Yoshida Y; Tanaka H; Oshiro T; Okazumi S; Katoh R
Support Care Cancer; 2014 Jun; 22(6):1579-84. PubMed ID: 24452412
[TBL] [Abstract][Full Text] [Related]
6. Protective effect of the oral administration of cystine and theanine on oxaliplatin-induced peripheral neuropathy: a pilot randomized trial.
Kobayashi M; Sato R; Komura T; Ichikawa H; Hirashima T; Otake S; Akazawa N; Yazawa T; Abe T; Okada T; Kakita T; Oikawa M; Tsuchiya T
Int J Clin Oncol; 2020 Oct; 25(10):1814-1821. PubMed ID: 32594273
[TBL] [Abstract][Full Text] [Related]
7. Time-dependent discrepancies between physician-assessed and patient-reported oxaliplatin-induced peripheral neuropathy in patients with metastatic colorectal cancer who received mFOLFOX6 plus bevacizumab: a post hoc analysis (WJOG4407GSS2).
Miura Y; Ando M; Yamazaki K; Hironaka S; Boku N; Muro K; Hyodo I
Support Care Cancer; 2021 Jul; 29(7):3715-3723. PubMed ID: 33200233
[TBL] [Abstract][Full Text] [Related]
8. A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy.
Kotaka M; Saito Y; Kato T; Satake H; Makiyama A; Tsuji Y; Shinozaki K; Fujiwara T; Mizushima T; Harihara Y; Nagata N; Kurihara N; Ando M; Kusakawa G; Sakai T; Uchida Y; Takamoto M; Kimoto S; Hyodo I
Cancer Chemother Pharmacol; 2020 Nov; 86(5):607-618. PubMed ID: 32965539
[TBL] [Abstract][Full Text] [Related]
9. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
Tournigand C; Cervantes A; Figer A; Lledo G; Flesch M; Buyse M; Mineur L; Carola E; Etienne PL; Rivera F; Chirivella I; Perez-Staub N; Louvet C; André T; Tabah-Fisch I; de Gramont A
J Clin Oncol; 2006 Jan; 24(3):394-400. PubMed ID: 16421419
[TBL] [Abstract][Full Text] [Related]
10. Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study.
Oki E; Emi Y; Kojima H; Higashijima J; Kato T; Miyake Y; Kon M; Ogata Y; Takahashi K; Ishida H; Saeki H; Sakaguchi Y; Yamanaka T; Kono T; Tomita N; Baba H; Shirabe K; Kakeji Y; Maehara Y
Int J Clin Oncol; 2015 Aug; 20(4):767-75. PubMed ID: 25627820
[TBL] [Abstract][Full Text] [Related]
11. Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV.
Vincenzi B; Frezza AM; Schiavon G; Spoto C; Silvestris N; Addeo R; Catalano V; Graziano F; Santini D; Tonini G
Support Care Cancer; 2013 May; 21(5):1313-9. PubMed ID: 23196819
[TBL] [Abstract][Full Text] [Related]
12. Predictive clinical factors of chronic peripheral neuropathy induced by oxaliplatin.
Yildirim N; Cengiz M
Support Care Cancer; 2020 Oct; 28(10):4781-4788. PubMed ID: 31974772
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of Oxaliplatin-induced Chronic Neuropathy and Influencing Factors in Patients with Colorectal Cancer in Iran.
Shahriari-Ahmadi A; Fahimi A; Payandeh M; Sadeghi M
Asian Pac J Cancer Prev; 2015; 16(17):7603-6. PubMed ID: 26625769
[TBL] [Abstract][Full Text] [Related]
14. The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen.
Nishioka M; Shimada M; Kurita N; Iwata T; Morimoto S; Yoshikawa K; Higashijima J; Miyatani T; Kono T
Int J Clin Oncol; 2011 Aug; 16(4):322-7. PubMed ID: 21258836
[TBL] [Abstract][Full Text] [Related]
15. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
Milla P; Airoldi M; Weber G; Drescher A; Jaehde U; Cattel L
Anticancer Drugs; 2009 Jun; 20(5):396-402. PubMed ID: 19287306
[TBL] [Abstract][Full Text] [Related]
16. Skin platinum deposition in colorectal cancer patients following oxaliplatin-based therapy.
Cao Y; Chang Q; Zhang W; Ornatsky O; Hedley D; Chen EX
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1195-1200. PubMed ID: 31520102
[TBL] [Abstract][Full Text] [Related]
17. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients.
Wang WS; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chiou TJ; Liu JH; Yen CC; Chen PM
Oncologist; 2007 Mar; 12(3):312-9. PubMed ID: 17405895
[TBL] [Abstract][Full Text] [Related]
18. Quantitative Sensory Testing at Baseline and During Cycle 1 Oxaliplatin Infusion Detects Subclinical Peripheral Neuropathy and Predicts Clinically Overt Chronic Neuropathy in Gastrointestinal Malignancies.
Reddy SM; Vergo MT; Paice JA; Kwon N; Helenowski IB; Benson AB; Mulcahy MF; Nimeiri HS; Harden RN
Clin Colorectal Cancer; 2016 Mar; 15(1):37-46. PubMed ID: 26337211
[TBL] [Abstract][Full Text] [Related]
19. A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration.
Beijers AJ; Mols F; Vreugdenhil G
Support Care Cancer; 2014 Jul; 22(7):1999-2007. PubMed ID: 24728618
[TBL] [Abstract][Full Text] [Related]
20. Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer.
Maindrault-Goebel F; Tournigand C; André T; Carola E; Mabro M; Artru P; Louvet C; de Gramont A
Ann Oncol; 2004 Aug; 15(8):1210-4. PubMed ID: 15277260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
